VALABREGA, Giorgio
Dettaglio
VALABREGA, Giorgio
ONCOLOGIA
Pubblicazioni
Risultati 1 - 20 di 71 (tempo di esecuzione: 0.001 secondi).
Titolo | Data di pubblicazione | Autore(i) | |
---|---|---|---|
1 | Abstract 3102: Identification of actionable cancer genes and treatment options for metastatic ovarian carcinomas using patient-derived xenografts and PDX-derived tumor cells | 2018 | Olivero, Martina; Erriquez, Jessica; Arigoni, Maddalena; Capellero, Sonia; D'Ambrosio, Concetta; Mittica, Gloria; Borella, Fulvio; Katsaros, Dionyssios; Privitera, Silvana; Berrino, Enrico; Venesio, Tiziana; Valabrega, Giorgio; Calogero, Raffaele; Renzo, Maria Flavia Di |
2 | Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives. | 2013 | Milani A;Sangiolo D;Montemurro F;Aglietta M;Valabrega G |
3 | Adoptive immunotherapy against ovarian cancer | 2016 | Mittica, Gloria; Capellero, Sonia; Genta, Sofia; Cagnazzo, Celeste; Aglietta, Massimo; Sangiolo, Dario; Valabrega, Giorgio |
4 | Androgen receptor status predicts development of brain metastases in ovarian cancers | 2017 | Mittica, Gloria; Senetta, Rebecca; Scotto, Giulia; Aglietta, Massimo; Maggiorotto, Furio; Ghisoni, Eleonora; Genta, Sofia; Boldorini, Renzo; Manini, Claudia; Morra, Isabella; Buosi, Roberta; Sapino, Anna; Cassoni, Paola; Valabrega, Giorgio |
5 | Are cyclin-dependent kinases 4/6 inhibitors ready for prime time in estrogen-receptor positive metastatic breast cancer? | 2017 | Genta, Sofia; Mittica, Gloria; Giannone, Gaia; Ghisoni, Eleonora; Valabrega, Giorgio |
6 | Assays of conventional chemotherapeutics and targeted drugs for ovarian cancer using patient derived models | 2019 | Concetta D’Ambrosio, Jessica Erriquez, Maddalena Arigoni, Sonia Capellero, Gloria Mittica, Eleonora Ghisoni, Fulvio Borella, Dionyssios Katsaros, Silvana Privitera, Marisa Ribotta, Elena Maldi, Giovanna Di Nardo, Enrico Berrino, Tiziana Venesio, Riccardo Ponzone, Marco Vaira, Douglas Hall, Mercedes Jimenez-Linan, Anna L. Paterson, Giorgio Valabrega, Raffaele A. Calogero, James D. Brenton, Maria Flavia Di Renzo and Martina Olivero |
7 | Brain Metastases from Ovarian Cancer: Current Evidence in Diagnosis, Treatment, and Prognosis | 2020 | Borella, Fulvio; Bertero, Luca; Morrone, Antonio; Gambella, Alessandro; Bovetti, Marialuisa; Cosma, Stefano; Carosso, Andrea; Katsaros, Dionyssios; Gemmiti, Silvia; Preti, Mario; Valabrega, Giorgio; Scotto, Giulia; Cassoni, Paola; Benedetto, Chiara |
8 | Buparlisib , an oral pan-PI3K inhibitor for the treatment of breast cancer | 2015 | Geuna, Elena; Milani, Andrea; Martinello, Rossella; Aversa, Caterina; Valabrega, Giorgio; Scaltriti, Maurizio; Montemurro, Filippo |
9 | CAR-Based Strategies beyond T Lymphocytes: Integrative Opportunities for Cancer Adoptive Immunotherapy | 2019 | Rotolo, Ramona; Leuci, Valeria; Donini, Chiara; Cykowska, Anna; Gammaitoni, Loretta; Medico, Giovanni; Valabrega, Giorgio; Aglietta, Massimo; Sangiolo, Dario |
10 | Checkpoint inhibitors in endometrial cancer: Preclinical rationale and clinical activity | 2017 | Mittica, Gloria; Ghisoni, Eleonora; Giannone, Gaia; Aglietta, Massimo; Genta, Sofia; Valabrega, Giorgio |
11 | Clinical implications of DNA repair defects in high-grade serous ovarian carcinomas | 2020 | Milanesio M.C.; Giordano S.; Valabrega G. |
12 | Concurrent radiotherapy does not affect adjuvant CMF delivery but is associated with increased toxicity in women with early breast cancer | 2006 | MONTEMURRO F; GATTI M; REDANA S; JACOMUZZI ME; NANNI D; DURANDO A; POPOLO M; PONZONE R; ROSSI A; ALBIERI V; VALABREGA G; SISMONDI P; GABRIELE P; AGLIETTA M |
13 | Controversies in breast cancer: adjuvant and neoadjuvant therapy | 2005 | F. MONTEMURRO; S. REDANA; G. VALABREGA; M. AGLIETTA |
14 | Current status and future perspectives in the endocrine treatment of postmenopausal, hormone receptor-positive metastatic breast cancer. | 2012 | Montemurro F; Rossi V; Geuna E; Valabrega G; Martinello R; Milani A; Aglietta M. |
15 | Cytoreductive Surgery for Heavily Pre-Treated, Platinum-Resistant Epithelial Ovarian Carcinoma: A Two-Center Retrospective Experience | 2020 | Tuninetti, Valentina; Di Napoli, Marilena; Ghisoni, Eleonora; Maggiorotto, Furio; Robella, Manuela; Scotto, Giulia; Giannone, Gaia; Turinetto, Margherita; Siatis, Dimitris; Ponzone, Riccardo; Vaira, Marco; De Simone, Michele; Scaffa, Cono; Pignata, Sandro; Greggi, Stefano; Di Maio, Massimo; Valabrega, Giorgio |
16 | Endometrial Cancer Stem Cells: Role, Characterization and Therapeutic Implications | 2019 | Giannone, Gaia; Attademo, Laura; Scotto, Giulia; Genta, Sofia; Ghisoni, Eleonora; Tuninetti, Valentina; Aglietta, Massimo; Pignata, Sandro; Valabrega, Giorgio |
17 | ErbB2 and bone sialoprotein as markers for metastatic osteosarcoma cells. | 2003 | VALABREGA G; FAGIOLI F; CORSO S; MADON E; BRACH DEL PREVER A; BIASIN E; LINARI A; M. AGLIETTA; GIORDANO S. |
18 | HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib | 2011 | Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F. |
19 | Hitting multiple targets in HER2-positive breast cancer: proof of principle or therapeutic opportunity? | 2011 | Geuna E; Milani A; Redana S; Rossi V; Valabrega G; Aglietta M; Montemurro F. |
20 | Hormone-receptor expression and activity of trastuzumab with chemotherapy in HER2-positive advanced breast cancer patients. | 2012 | Montemurro F; Rossi V; Rocca MC; Martinello R; Verri E; Redana S; Adamoli L; Valabrega G; Sapino A; Aglietta M; Viale G; Goldhirsch A; Nolè F. |